Delaware (State or other jurisdiction of incorporation) | 001-16391 (Commission File Number) | 86-0741227 (IRS Employer Identification No.) |
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Exhibit Number | Exhibit Description | |
99.1 |
Dated:May 9, 2019 | Axon Enterprise, Inc. | |||
By: | /s/ JAWAD A. AHSAN | |||
Jawad A. Ahsan | ||||
Chief Financial Officer |
• | Record quarterly revenue of $116 million, up 14% year over year |
• | GAAP EPS of $0.11 and Non-GAAP EPS of $0.21 |
• | Adjusted EBITDA of $14 million |
• | $329 million of cash and investments, and no debt at quarter end |
• | Raising full year revenue guidance to $485 million to $495 million |
• | Revenue of $116 million represents 14% year over year growth. |
• | Gross margin of 59.5% represents 260 basis points of sequential improvement, driven by strength in software and sensors, partially offset by TASER 7 program startup costs, including customer trade-in credits. |
• | Operating expenses of $66.2 million reflect continued R&D investment and SG&A expense discipline. |
◦ | SG&A of $42.9 million grew 2% sequentially. |
◦ | R&D of $23.4 million grew 10% sequentially on increases in headcount to support software product development. |
• | GAAP EPS of $0.11 includes a tax benefit related to the vesting of employee stock grants; Non-GAAP EPS of $0.21 excludes non-cash stock-based compensation expenses and also reflects the benefit of a favorable tax rate. |
• | Adjusted EBITDA of $14 million grew 27% or $3 million sequentially, primarily due to the rationalization of non-recurring expenses associated with Vievu, which we acquired in May 2018. |
• | Axon's strong balance sheet, which includes $329 million in cash and investments, and zero debt, provides us with the latitude to continue growing our subscription contracts as a percentage of revenue. |
Three Months Ended | Change | ||||||||||||||||
March 31, 2019 | December 31, 2018 | March 31, 2018 | QoQ | YoY | |||||||||||||
TASER | |||||||||||||||||
Net sales | $ | 65,391 | $ | 65,301 | $ | 63,524 | 0.1 | % | 2.9 | % | |||||||
Gross margin | 64.4 | % | 65.0 | % | 67.7 | % | -60bp | -330bp |
• | TASER revenue of $65.3 million, up 3% year over year, includes strength in legacy product pricing, strong UK sales and a 19% year over year increase in cartridge sales. |
◦ | The 8,800 TASER 7 units shipped in Q1 2019 represents unit volume on par with the entire first year of the TASER X2, which we introduced in 2011. |
• | TASER gross margin of 64.4% declined sequentially, largely driven by a dip in TASER 7 ASPs due to customer trade-in credits, combined with TASER 7 manufacturing yields that have not yet reached maturity. We also began depreciating TASER 7 production equipment for a full quarter. We expect TASER segment gross margins to strengthen in the back half. |
• | Approximately 42% of all weapons sold in Q1 were on a recurring payment plan. In the United States, recurring payment plans accounted for 51% of new TASER contracts, with TASER 7 contracts driving subscriptions. |
Three Months Ended | Change | ||||||||||||||||
March 31, 2019 | December 31, 2018 | March 31, 2018 | QoQ | YoY | |||||||||||||
Software and Sensors | |||||||||||||||||
Axon Cloud net sales | $ | 27,631 | $ | 25,774 | $ | 20,241 | 7.2 | % | 36.5 | % | |||||||
Axon Cloud gross margin | 73.6 | % | 74.5 | % | 78.7 | % | -90bp | -510bp | |||||||||
Sensors and Other net sales | $ | 22,788 | $ | 23,716 | $ | 17,450 | (3.9 | )% | 30.6 | % | |||||||
Sensors and Other gross margin | 28.4 | % | 15.7 | % | 31.9 | % | 1,270bp | -350bp |
• | Axon Cloud revenue of $27.6 million grew 37% year over year. |
• | Axon Cloud gross margin of 73.6% was in line with our expectations. |
• | Sensors and Other revenue of $22.8 million grew 31% year over year and was down sequentially, reflecting typical seasonality and an anticipated slowdown of Axon Body 2 sales in advance of Axon Body 3 coming to market in Q3. We expect hardware revenue to strengthen in the back half of 2019 with the commencement of AB3 shipments. |
• | Sensors and Other gross margin of 28.4% was up substantially from 15.7% in Q4 2018, primarily due to the rationalization of one-time expenses associated with Vievu. As previously discussed, we manage to a 25% gross margin in sensors hardware, though it may vary quarter to quarter depending on mix. |
March 31, 2019 | December 31, 2018 | September 30, 2018 | June 30, 2018 | March 31, 2018 | |||||||||||||||
Annual recurring revenue (1) | $ | 122,276 | $ | 108,496 | $ | 101,618 | $ | 92,711 | $ | 83,310 | |||||||||
Cumulative Axon software seats booked | 371,100 | 347,200 | 325,200 | 305,200 | 226,900 | ||||||||||||||
Software and Sensors bookings | $ | 76,391 | $ | 109,779 | $ | 92,895 | $ | 88,860 | $ | 97,528 | |||||||||
Total company future contracted revenue | $ | 930,000 | $ | 900,000 | $ | 820,000 | $ | 750,000 | $ | 650,000 |
• | Note that annual recurring revenue of $122 million is driven by only that portion of Axon's (371,100 cumulative) booked seats that are online and contributing to revenue. For the first time, annual recurring revenue includes software and warranty revenue related to TASER 7, which is our first true subscription-hardware TASER with software connectivity, a dock and cloud data storage. The strong sequential growth in ARR primarily reflects strength in domestic body camera and Axon Fleet software licenses. As we anticipated, the contribution from TASER 7 was minimal. |
• | For the first time, cumulative Axon booked seats includes TASER 7 software licenses. |
• | Software and Sensors bookings of $76 million reflect typical Q1 seasonality, which we did not experience in Q1 2018 due to a substantial international order. Excluding that single order one year ago, bookings grew on a year-over-year basis. We anticipate that bookings will strengthen after Axon Body 3 begins shipping in Q3 2019. |
• | Total company future contracted revenue of approximately $930 million is limited to revenue from arrangements that meet the definition of a contract under Topic 606 as of March 31, 2019. We expect to recognize between 15% to 20% of this balance over the next 12 months and expect the remainder to be recognized over the following five to seven years, subject to risks related to delayed deployments, budget appropriation or other contract cancellation clauses. |
• | Axon's bundled subscription offerings should drive margins higher as they constitute a greater share of customer mix. |
• | Raising revenue outlook to $485 million to $495 million, from $480 million to $490 million previously; |
◦ | We continue to expect to deliver significantly higher growth rates in the second half of 2019, driven by an anticipated acceleration of TASER 7 shipments and initial Axon Body 3 shipments. |
◦ | Q2 2019 revenue is expected to increase approximately 16% to 17% year over year; |
• | Maintaining Adjusted EBITDA guidance of $80 million to $85 million, which represents 34% year-over-year growth at the midpoint; |
◦ | Adjusted EBITDA in Q2 2019 is expected to be approximately flat sequentially and year over year. |
• | We expect stock-based compensation expenses to be approximately $35 million for the full year, which is subject to change depending on our assessment of the probability of attaining operational metrics for the CEO Performance Award and XSU awards, and the expected timing of such attainment; and |
• | A normalized tax rate of 20% to 25%, which can fluctuate depending on geography of income and the effects of discrete items, including changes in our stock price. |
• | EBITDA (Most comparable GAAP Measure: Net income) - Earnings before interest expense, investment interest income, income taxes, depreciation and amortization. |
• | Adjusted EBITDA (Most comparable GAAP Measure: Net income) - Earnings before interest expense, investment interest income, income taxes, depreciation, amortization, non-cash stock-based compensation expense and pre-tax certain other items (described below). |
• | Non-GAAP Net Income (Most comparable GAAP Measure: Net income) - Net income excluding the costs of non-cash stock-based compensation and excluding pre-tax certain other items, including, but not limited to, net gain/loss/write-down/disposal/abandonment of property, equipment and intangible assets; loss on impairment; and costs related to business acquisitions. The Company tax-effects non-GAAP adjustments using the blended statutory federal and state tax rates for each period presented. |
• | Non-GAAP Diluted Earnings Per Share (Most comparable GAAP Measure: Earnings Per share) - Measure of Company's Non-GAAP Net Income divided by the weighted average number of diluted common shares outstanding during the period presented. |
• | Free Cash Flow (Most comparable GAAP Measure: Cash flow from operating activities) - cash flows provided by operating activities minus purchases of property and equipment, intangible assets and cash flows related to business acquisitions. |
• | these non-GAAP financial measures are limited in their usefulness and should be considered only as a supplement to the Company's GAAP financial measures; |
• | these non-GAAP financial measures should not be considered in isolation from, or as a substitute for, the Company's GAAP financial measures; |
• | these non-GAAP financial measures should not be considered to be superior to the Company's GAAP financial measures; and |
• | these non-GAAP financial measures were not prepared in accordance with GAAP and investors should not assume that the non-GAAP financial measures presented in this earnings release were prepared under a comprehensive set of rules or principles. |
• | Axon on Twitter: https://twitter.com/axon_us |
• | Axon on Facebook: https://www.facebook.com/Axon.ProtectLife/ |
Three Months Ended | |||||||||||
March 31, 2019 | December 31, 2018 | March 31, 2018 | |||||||||
Net sales from products | $ | 88,089 | $ | 89,017 | $ | 80,974 | |||||
Net sales from services | 27,721 | 25,774 | 20,241 | ||||||||
Net sales | 115,810 | 114,791 | 101,215 | ||||||||
Cost of product sales | 39,600 | 42,863 | 32,434 | ||||||||
Cost of service sales | 7,293 | 6,582 | 4,320 | ||||||||
Cost of sales | 46,893 | 49,445 | 36,754 | ||||||||
Gross margin | 68,917 | 65,346 | 64,461 | ||||||||
Operating expenses: | |||||||||||
Sales, general and administrative | 42,892 | 42,099 | 35,759 | ||||||||
Research and development | 23,354 | 21,254 | 15,119 | ||||||||
Total operating expenses | 66,246 | 63,353 | 50,878 | ||||||||
Income from operations | 2,671 | 1,993 | 13,583 | ||||||||
Interest and other income, net | 2,313 | 1,021 | 1,263 | ||||||||
Income before provision for income taxes | 4,984 | 3,014 | 14,846 | ||||||||
Provision for (benefit from) income taxes | (1,435 | ) | 931 | 1,920 | |||||||
Net income | $ | 6,419 | $ | 2,083 | $ | 12,926 | |||||
Net income per common and common equivalent shares: | |||||||||||
Basic | $ | 0.11 | $ | 0.04 | $ | 0.24 | |||||
Diluted | $ | 0.11 | $ | 0.03 | $ | 0.24 | |||||
Weighted average number of common and common equivalent shares outstanding: | |||||||||||
Basic | 58,914 | 58,502 | 53,119 | ||||||||
Diluted | 59,751 | 59,665 | 54,532 |
Three Months Ended March 31, 2019 | Three Months Ended December 31, 2018 | Three Months Ended March 31, 2018 | |||||||||||||||||||||||||||||||||
TASER | Software and Sensors | Total | TASER | Software and Sensors | Total | TASER | Software and Sensors | Total | |||||||||||||||||||||||||||
Net sales from products (1) | $ | 65,301 | $ | 22,788 | $ | 88,089 | $ | 65,301 | $ | 23,716 | $ | 89,017 | $ | 63,524 | $ | 17,450 | $ | 80,974 | |||||||||||||||||
Net sales from services (2) | 90 | 27,631 | 27,721 | — | 25,774 | 25,774 | — | 20,241 | 20,241 | ||||||||||||||||||||||||||
Net sales | 65,391 | 50,419 | 115,810 | 65,301 | 49,490 | 114,791 | 63,524 | 37,691 | 101,215 | ||||||||||||||||||||||||||
Cost of product sales | 23,278 | 16,322 | 39,600 | 22,874 | 19,989 | 42,863 | 20,543 | 11,891 | 32,434 | ||||||||||||||||||||||||||
Cost of service sales | — | 7,293 | 7,293 | — | 6,582 | 6,582 | — | 4,320 | 4,320 | ||||||||||||||||||||||||||
Cost of sales | 23,278 | 23,615 | 46,893 | 22,874 | 26,571 | 49,445 | 20,543 | 16,211 | 36,754 | ||||||||||||||||||||||||||
Gross margin | 42,113 | 26,804 | 68,917 | 42,427 | 22,919 | 65,346 | 42,981 | 21,480 | 64,461 | ||||||||||||||||||||||||||
Gross margin % | 64.4 | % | 53.2 | % | 59.5 | % | 65.0 | % | 46.3 | % | 56.9 | % | 67.7 | % | 57.0 | % | 63.7 | % | |||||||||||||||||
Research and development | 3,712 | 19,642 | 23,354 | 5,196 | 16,058 | 21,254 | 2,960 | 12,159 | 15,119 |
Three Months Ended March 31, | |||||||||||
2019 | 2018 | Unit Change | Percent Change | ||||||||
TASER 7 | 8,835 | — | 8,835 | * | |||||||
TASER X26P | 14,985 | 15,720 | (735 | ) | (4.7 | ) | |||||
TASER X2 | 9,861 | 20,501 | (10,640 | ) | (51.9 | ) | |||||
TASER Pulse and Bolt | 1,253 | 4,000 | (2,747 | ) | (68.7 | ) | |||||
Cartridges | 616,517 | 532,952 | 83,565 | 15.7 | |||||||
Axon Body | 25,848 | 21,769 | 4,079 | 18.7 | |||||||
Axon Flex | 3,591 | 3,693 | (102 | ) | (2.8 | ) | |||||
Axon Fleet | 1,735 | 1,857 | (122 | ) | (6.6 | ) | |||||
Axon Dock | 4,994 | 5,844 | (850 | ) | (14.5 | ) | |||||
TASER Cam | 1,741 | 3,528 | (1,787 | ) | (50.7 | ) |
Three Months Ended | |||||||||||
March 31, 2019 | December 31, 2018 | March 31, 2018 | |||||||||
EBITDA and Adjusted EBITDA: | |||||||||||
Net income | $ | 6,419 | $ | 2,083 | $ | 12,926 | |||||
Depreciation and amortization | 2,800 | 2,389 | 2,411 | ||||||||
Interest expense | 6 | 33 | 20 | ||||||||
Investment interest income | (2,003 | ) | (1,076 | ) | (75 | ) | |||||
Provision for (benefit from) income taxes | (1,435 | ) | 931 | 1,920 | |||||||
EBITDA | $ | 5,787 | $ | 4,360 | $ | 17,202 | |||||
Adjustments: | |||||||||||
Stock-based compensation expense | $ | 7,905 | $ | 6,577 | $ | 4,093 | |||||
Loss on disposal and abandonment of intangible assets | 18 | 14 | — | ||||||||
Loss on disposal and impairment of property and equipment, net | 242 | 13 | 34 | ||||||||
Adjusted EBITDA | $ | 13,952 | $ | 10,964 | $ | 21,329 | |||||
Net income as a percentage of net sales | 5.5 | % | 1.8 | % | 12.8 | % | |||||
Adjusted EBITDA as a percentage of net sales | 12.0 | % | 9.6 | % | 21.1 | % | |||||
Stock-based compensation expense: | |||||||||||
Cost of product and service sales | $ | 226 | $ | 152 | $ | 141 | |||||
Sales, general and administrative | 4,681 | 3,927 | 2,304 | ||||||||
Research and development | 2,998 | 2,498 | 1,648 | ||||||||
Total | $ | 7,905 | $ | 6,577 | $ | 4,093 |
Three Months Ended | |||||||||||
March 31, 2019 | December 31, 2018 | March 31, 2018 | |||||||||
Non-GAAP net income: | |||||||||||
GAAP net income | $ | 6,419 | $ | 2,083 | $ | 12,926 | |||||
Non-GAAP adjustments: | |||||||||||
Stock-based compensation expense | 7,905 | 6,577 | 4,093 | ||||||||
Loss on disposal and abandonment of intangible assets | 18 | 14 | — | ||||||||
Loss on disposal and impairment of property and equipment, net | 242 | 13 | 34 | ||||||||
Income tax effects | (2,016 | ) | (1,737 | ) | (1,002 | ) | |||||
Income tax benefit of CEO stock option exercise | — | (2,321 | ) | — | |||||||
Non-GAAP net income | $ | 12,568 | $ | 4,629 | $ | 16,051 |
Three Months Ended | |||||||||||
March 31, 2019 | December 31, 2018 | March 31, 2018 | |||||||||
Non-GAAP diluted earnings per share: | |||||||||||
GAAP diluted earnings per share | $ | 0.11 | $ | 0.03 | $ | 0.24 | |||||
Non-GAAP adjustments: | |||||||||||
Stock-based compensation expense | 0.13 | 0.11 | 0.08 | ||||||||
Loss on disposal and abandonment of intangible assets | 0.00 | — | — | ||||||||
Loss on disposal and impairment of property and equipment, net | 0.00 | 0.00 | — | ||||||||
Income tax effects | (0.03 | ) | (0.03 | ) | (0.02 | ) | |||||
Income tax benefit of CEO stock option exercise | — | (0.04 | ) | — | |||||||
Non-GAAP diluted earnings per share (1) | $ | 0.21 | $ | 0.08 | $ | 0.29 | |||||
Weighted average number of diluted common and common equivalent shares outstanding (in thousands) | 59,751 | 59,665 | 54,532 |
March 31, 2019 | December 31, 2018 | ||||||
(Unaudited) | |||||||
ASSETS | |||||||
Current Assets: | |||||||
Cash and cash equivalents | $ | 223,642 | $ | 349,462 | |||
Short-term investments | 105,312 | — | |||||
Accounts and notes receivable, net | 149,096 | 130,579 | |||||
Contract assets, net | 17,945 | 13,960 | |||||
Inventory | 37,587 | 33,763 | |||||
Prepaid expenses and other current assets | 33,340 | 30,391 | |||||
Total current assets | 566,922 | 558,155 | |||||
Property and equipment, net | 41,347 | 37,893 | |||||
Deferred income tax assets, net | 18,770 | 19,347 | |||||
Intangible assets, net | 15,067 | 15,935 | |||||
Goodwill | 25,017 | 24,981 | |||||
Long-term notes receivable, net of current portion | 36,316 | 40,230 | |||||
Other assets | 35,756 | 22,999 | |||||
Total assets | $ | 739,195 | $ | 719,540 | |||
LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
Current Liabilities: | |||||||
Accounts payable | $ | 9,865 | $ | 15,164 | |||
Accrued liabilities | 36,348 | 41,092 | |||||
Current portion of deferred revenue | 110,063 | 107,016 | |||||
Customer deposits | 3,604 | 2,702 | |||||
Other current liabilities | 3,914 | 37 | |||||
Total current liabilities | 163,794 | 166,011 | |||||
Deferred revenue, net of current portion | 74,784 | 74,417 | |||||
Liability for unrecognized tax benefits | 3,156 | 2,849 | |||||
Long-term deferred compensation | 3,675 | 3,235 | |||||
Other long-term liabilities | 13,247 | 5,704 | |||||
Total liabilities | 258,656 | 252,216 | |||||
Stockholders’ Equity: | |||||||
Preferred stock | — | — | |||||
Common stock | 1 | 1 | |||||
Additional paid-in capital | 460,146 | 453,400 | |||||
Treasury stock | (155,947 | ) | (155,947 | ) | |||
Retained earnings | 177,802 | 171,383 | |||||
Accumulated other comprehensive loss | (1,463 | ) | (1,513 | ) | |||
Total stockholders’ equity | 480,539 | 467,324 | |||||
Total liabilities and stockholders’ equity | $ | 739,195 | $ | 719,540 |
Three Months Ended | |||||||||||
March 31, 2019 | December 31, 2018 | March 31, 2018 | |||||||||
Cash flows from operating activities: | |||||||||||
Net income | $ | 6,419 | $ | 2,083 | $ | 12,926 | |||||
Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
Depreciation and amortization | 2,800 | 2,389 | 2,411 | ||||||||
Loss on disposal and abandonment of intangible assets | 18 | 1,827 | — | ||||||||
Loss (gain) on disposal and impairment of property and equipment, net | 242 | (1,800 | ) | 34 | |||||||
Stock-based compensation | 7,905 | 6,577 | 4,093 | ||||||||
Deferred income taxes | 577 | (1,266 | ) | 1,514 | |||||||
Unrecognized tax benefits | 307 | 1,045 | 104 | ||||||||
Other noncash, net | 896 | — | 22 | ||||||||
Change in assets and liabilities: | |||||||||||
Accounts and notes receivable | (21,994 | ) | (16,471 | ) | (17,060 | ) | |||||
Inventory | (3,936 | ) | 5,771 | 2,408 | |||||||
Prepaid expenses and other assets | (3,152 | ) | (658 | ) | (1,702 | ) | |||||
Accounts payable, accrued liabilities and other liabilities | (7,284 | ) | 9,200 | 6,740 | |||||||
Deferred revenue | 3,232 | 22,542 | 6,554 | ||||||||
Net cash provided by (used in) operating activities | (13,970 | ) | 31,239 | 18,044 | |||||||
Cash flows from investing activities: | |||||||||||
Purchases of investments | (105,322 | ) | — | (802 | ) | ||||||
Proceeds from call / maturity of investments | — | 500 | 3,167 | ||||||||
Purchases of property and equipment | (5,271 | ) | (4,259 | ) | (1,063 | ) | |||||
Purchases of intangible assets | (162 | ) | (98 | ) | (34 | ) | |||||
Net cash provided by (used in) investing activities | (110,755 | ) | (3,857 | ) | 1,268 | ||||||
Cash flows from financing activities: | |||||||||||
Proceeds from options exercised | 100 | 1,044 | 356 | ||||||||
Income and payroll tax payments for net-settled stock awards | (1,259 | ) | (2,154 | ) | (3,777 | ) | |||||
Payment of contingent consideration for business acquisitions | — | (1,700 | ) | — | |||||||
Net cash used in financing activities | (1,159 | ) | (2,810 | ) | (3,421 | ) | |||||
Effect of exchange rate changes on cash and cash equivalents | 67 | (393 | ) | 469 | |||||||
Net increase (decrease) in cash and cash equivalents | (125,817 | ) | 24,179 | 16,360 | |||||||
Cash and cash equivalents, beginning of period | 351,027 | 326,848 | 78,438 | ||||||||
Cash and cash equivalents, end of period | $ | 225,210 | $ | 351,027 | $ | 94,798 |
Three Months Ended | |||||||||||
March 31, 2019 | December 31, 2018 | March 31, 2018 | |||||||||
Cash and cash equivalents | $ | 223,642 | $ | 349,462 | $ | 92,330 | |||||
Restricted cash | 1,568 | 1,565 | 2,468 | ||||||||
Cash, cash equivalents and restricted cash, end of period | $ | 225,210 | $ | 351,027 | $ | 94,798 |
Three Months Ended | |||||||||||
March 31, 2019 | December 31, 2018 | March 31, 2018 | |||||||||
Net cash provided by (used in) operating activities | $ | (13,970 | ) | $ | 31,239 | $ | 18,044 | ||||
Purchases of property and equipment | (5,271 | ) | (4,259 | ) | (1,063 | ) | |||||
Purchases of intangible assets | (162 | ) | (98 | ) | (34 | ) | |||||
Free cash flow (deficit), a non-GAAP measure | $ | (19,403 | ) | $ | 26,882 | $ | 16,947 |
=+PM*I$GEAS&8P-NXC.&)&
M>AK >O6H+OP
MSJ?]K2WUJ;20G4TO4CDE9,J(=F"0AP<^QXKKJ*7(EM_7]6'S,YMO#]Y/I.O>
M>UNM]JZD;49C'$/+V*-Q&3TR3@=>E53X8NG\/MIT.FZ5I[EX&,EM*3YI1P26
M_=+S@''7K7744 F72O<6443[B7AQ&3+&ZC."> #\O7K2;M^/Y-C2N=
M9!/%;+;3^M32?XFZ=$T=O-I.JQZBVHKIKZ
(/^_^
MG_\ R57244
?Z_
MK\?N!:V_K^NAZG17DOANQUV_:/3;^YUYM.&M$_:,7UFSVYLB<;II&F5/-]7^
M]Z9 K3\)1>(AX_NWU:\U(C?